Company intelligence / Profile preview

Oxis Biotech, Inc.

Tampa, Florida, United Statesgtbiopharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Oxis Biotech developed preclinical-stage immuno-oncology drugs targeting cancer using antibody-drug conjugates and small molecule inhibitors. Its lead program included an ADC for breast cancer in preclinical development and a P62-ZZ inhibitor for multiple myeloma that received a U.S. patent but had not yet entered clinical trials as of the last public disclosures.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugatesSmall moleculesCannabinoids
Industry: Biotech

Drug pipeline

2 assets

OXS-1550

Phase 2

Indications: B-cell lymphoma, Leukemia

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with cannabinoid researchers/institutions

Beyond the preview

Go deeper on Oxis Biotech, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxis Biotech, Inc..

Explore the full profile